ErbB-targeted therapeutic approaches in human cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The overexpression and aberrant function of the epidermal growth factor receptor (EGFR, erbB1, HER1) and its ligands and coreceptors in a wide spectrum of epithelial cancers have provided a rationale for targeting this signaling network with novel treatment approaches. Several antireceptor therapeutic strategies have been pursued, but two stand ahead in their clinical development. One approach has been the generation of small molecules that compete with adenosine triphosphate (ATP) for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. The second approach utilizes humanized monoclonal antibodies generated against the receptor's ligand-binding extracellular domain. These antibodies block binding of receptor-activating ligands and, in some cases, can induce receptor endocytosis and downregulation. Clinical studies already suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas.

Original languageEnglish (US)
Title of host publicationThe EGF Receptor Family
Subtitle of host publicationBiologic Mechanisms and Role in Cancer
PublisherElsevier Inc.
Pages127-135
Number of pages9
ISBN (Electronic)9780080472584
ISBN (Print)9780121602819
DOIs
StatePublished - Dec 19 2003

Fingerprint

Ligands
Antibodies, Monoclonal, Humanized
Neoplasms
Endocytosis
Epidermal Growth Factor Receptor
Signal Transduction
Phosphotransferases
Therapeutics
Down-Regulation
Adenosine Triphosphate
Carcinoma
Antibodies
Clinical Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Arteaga, C. L. (2003). ErbB-targeted therapeutic approaches in human cancer. In The EGF Receptor Family: Biologic Mechanisms and Role in Cancer (pp. 127-135). Elsevier Inc.. https://doi.org/10.1016/B978-012160281-9/50011-6

ErbB-targeted therapeutic approaches in human cancer. / Arteaga, Carlos L.

The EGF Receptor Family: Biologic Mechanisms and Role in Cancer. Elsevier Inc., 2003. p. 127-135.

Research output: Chapter in Book/Report/Conference proceedingChapter

Arteaga, CL 2003, ErbB-targeted therapeutic approaches in human cancer. in The EGF Receptor Family: Biologic Mechanisms and Role in Cancer. Elsevier Inc., pp. 127-135. https://doi.org/10.1016/B978-012160281-9/50011-6
Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. In The EGF Receptor Family: Biologic Mechanisms and Role in Cancer. Elsevier Inc. 2003. p. 127-135 https://doi.org/10.1016/B978-012160281-9/50011-6
Arteaga, Carlos L. / ErbB-targeted therapeutic approaches in human cancer. The EGF Receptor Family: Biologic Mechanisms and Role in Cancer. Elsevier Inc., 2003. pp. 127-135
@inbook{1d7c2c8929104c8d9285a64d42b95a6e,
title = "ErbB-targeted therapeutic approaches in human cancer",
abstract = "The overexpression and aberrant function of the epidermal growth factor receptor (EGFR, erbB1, HER1) and its ligands and coreceptors in a wide spectrum of epithelial cancers have provided a rationale for targeting this signaling network with novel treatment approaches. Several antireceptor therapeutic strategies have been pursued, but two stand ahead in their clinical development. One approach has been the generation of small molecules that compete with adenosine triphosphate (ATP) for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. The second approach utilizes humanized monoclonal antibodies generated against the receptor's ligand-binding extracellular domain. These antibodies block binding of receptor-activating ligands and, in some cases, can induce receptor endocytosis and downregulation. Clinical studies already suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas.",
author = "Arteaga, {Carlos L.}",
year = "2003",
month = "12",
day = "19",
doi = "10.1016/B978-012160281-9/50011-6",
language = "English (US)",
isbn = "9780121602819",
pages = "127--135",
booktitle = "The EGF Receptor Family",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - ErbB-targeted therapeutic approaches in human cancer

AU - Arteaga, Carlos L.

PY - 2003/12/19

Y1 - 2003/12/19

N2 - The overexpression and aberrant function of the epidermal growth factor receptor (EGFR, erbB1, HER1) and its ligands and coreceptors in a wide spectrum of epithelial cancers have provided a rationale for targeting this signaling network with novel treatment approaches. Several antireceptor therapeutic strategies have been pursued, but two stand ahead in their clinical development. One approach has been the generation of small molecules that compete with adenosine triphosphate (ATP) for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. The second approach utilizes humanized monoclonal antibodies generated against the receptor's ligand-binding extracellular domain. These antibodies block binding of receptor-activating ligands and, in some cases, can induce receptor endocytosis and downregulation. Clinical studies already suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas.

AB - The overexpression and aberrant function of the epidermal growth factor receptor (EGFR, erbB1, HER1) and its ligands and coreceptors in a wide spectrum of epithelial cancers have provided a rationale for targeting this signaling network with novel treatment approaches. Several antireceptor therapeutic strategies have been pursued, but two stand ahead in their clinical development. One approach has been the generation of small molecules that compete with adenosine triphosphate (ATP) for binding to the receptor's kinase pocket, thus blocking receptor activation and the transduction of postreceptor signals. The second approach utilizes humanized monoclonal antibodies generated against the receptor's ligand-binding extracellular domain. These antibodies block binding of receptor-activating ligands and, in some cases, can induce receptor endocytosis and downregulation. Clinical studies already suggest that both of these approaches, either alone or in combination with standard anticancer therapies, are well tolerated and can induce clinical responses and tumor stabilization in a variety of common carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=84942090688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942090688&partnerID=8YFLogxK

U2 - 10.1016/B978-012160281-9/50011-6

DO - 10.1016/B978-012160281-9/50011-6

M3 - Chapter

AN - SCOPUS:84942090688

SN - 9780121602819

SP - 127

EP - 135

BT - The EGF Receptor Family

PB - Elsevier Inc.

ER -